Molbio Diagnostics’ ProRad X-Ray Device Accelerates Early TB Detection in 100-Day Challenge

–        A total of 72,51,889 devices of Truenat were installed in public setups and 8,193 in private setups nationally

‘Bengaluru, March 21, 2025: The Government of India initiated the ambitious 100-Day TB Challenge aiming to accelerate nationwide efforts to screen, detect, and treat tuberculosis, reinforcing the country’s goal of eradicating the disease by 2025. This proactive health campaign sought to significantly improve early diagnosis and timely treatment interventions, particularly in remote and underserved regions. Molbio Diagnostics played a pivotal role in supporting this government initiative by deploying its cutting-edge diagnostic solutions, including the ultraportable ProRad Altas X-ray devices and the innovative Truenat molecular diagnostic platforms, which substantially enhanced the efficiency and reach of TB screening efforts across India.

Molbio Diagnostics commemorated World Tuberculosis Day by highlighting the successful completion of India’s ambitious 100-Day TB Challenge, showcasing the extensive deployment and impactful performance of its cutting-edge diagnostic solutions. Central to this campaign were the ultraportable ProRad X-ray devices and the innovative Truenat molecular diagnostic platforms, offering an end-to-end TB screening and diagnosis solution that significantly enhanced screening, early diagnosis, and rapid detection of tuberculosis across the country. The strategic deployment of these advanced diagnostic tools reached extensive coverage across India’s diverse regions, with 8 ProRad devices in the North region, 21 ProRad units in the South region, 20 ProRad units in the East region, and 49 ProRad units in the West region.

The ProRad Atlas, an ultraportable x-ray device acclaimed for its portability and accuracy, facilitated rapid chest X-ray screenings, enabling early-stage identification of presumptive TB cases even in remote and underserved areas. Complementing these efforts, Molbio’s revolutionary Truenat platform—a portable, battery-operated real-time PCR platform—provided rapid, point-of-care TB detection, confirming cases with high accuracy in under an hour. Together, these technologies significantly accelerated India’s capacity for proactive screening, diagnosis, and treatment nationwide within the 100-day period.

Speaking on the success of the initiative, Mr. Sriram Natarajan, CEO of Molbio Diagnostics, remarked, “Molbio Diagnostics is committed to positively impacting public health through innovative and accessible diagnostic solutions. Our ProRad Atlas, and Truenat platforms represent our dedication to enhancing the healthcare ecosystem by enabling timely and accurate TB diagnosis, especially in underserved areas. We remain dedicated to supporting India’s vision of eliminating tuberculosis by 2025 and will continue driving advancements that strengthen public health outcomes nationwide.”